The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.
Immunocore, a UK-based immunotherapy developer that traces its origins to University of Oxford, has secured $75m in a series C round led by an unnamed returning investor.
The round included accounts and vehicles for investment management firm BlackRock as well as undisclosed existing backers. In addition, Oxford Finance supplied $100m in debt financing.
Immunocore is working on T-cell receptor (TCR)-based drugs, which introduce modified white blood cells in the immune system in a bid to fight infectious and autoimmune…
